{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:18:22Z","timestamp":1778933902654,"version":"3.51.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1177,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1111\/j.1365-2133.2012.10940.x","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T18:22:13Z","timestamp":1331662933000},"page":"417-423","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study"],"prefix":"10.1093","volume":"167","author":[{"given":"M.","family":"Viguier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"S\u00e9neschal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Dubertret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-J.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bachelez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Groupe Fran\u00e7ais de Recherche sur le Psoriasis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,6,11]]},"reference":[{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2133.2006.07675.x","article-title":"A classification of psoriasis vulgaris according to phenotype","volume":"156","author":"Griffiths","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0190-9622(89)70287-5","article-title":"Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients","volume":"21","author":"Boyd","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0151-9638(05)79222-X","article-title":"Formes graves de psoriasis: 160 cas","volume":"132","author":"Jalal","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","article-title":"Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"159","author":"Schmitt","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1365-2133.2010.09707.x","article-title":"Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis","volume":"162","author":"Langley","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archderm.138.5.644","article-title":"The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases","volume":"138","author":"O\u2019Quinn","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/09546630310010895","article-title":"Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab","volume":"14","author":"Rongioletti","year":"2003","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/archderm.141.12.1607","article-title":"Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis","volume":"141","author":"Heikkil\u00e4","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2133.2006.07639.x","article-title":"A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity","volume":"156","author":"Poulalhon","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2133.2007.08111.x","article-title":"Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis","volume":"157","author":"Takahashi","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB16|cit16","first-page":"357","article-title":"Erythrodermic psoriasis successfully treated with efalizumab","volume":"18","author":"Piccirillo","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1440-0960.2008.00463.x","article-title":"From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis","volume":"49","author":"Yip","year":"2008","journal-title":"Australas J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1365-2133.2010.09669.x","article-title":"Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies","volume":"162","author":"Santos-Juanes","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D38MM3F315","article-title":"Long-term management of erythrodermic psoriasis with anti-TNF agents","volume":"16","author":"Romero-Mat\u00e9","year":"2010","journal-title":"Dermatol Online J"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2133.2006.07217.x","article-title":"Treatment of erythrodermic psoriasis with etanercept","volume":"155","author":"Esposito","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0190-9622(96)90078-X","article-title":"Infectious complications of erythrodermic psoriasis","volume":"34","author":"Green","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB23|cit23","first-page":"89","volume-title":"Psoriasis: Proceedings of the International Symposium","author":"Marks","year":"1971"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1001\/jama.1932.02740770032007","article-title":"Erythroderma psoriaticum: a review of 22 cases","volume":"99","author":"Goeckerman","year":"1932","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB25|cit25","first-page":"97","article-title":"Psoriasis: \u00e9volution et complications mortelles","volume":"118","author":"Roth","year":"1991","journal-title":"Ann Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2011.01224.x","article-title":"Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series","volume":"38","author":"Wang","year":"2011","journal-title":"J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1111\/j.1529-8019.2009.01266.x","article-title":"Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab","volume":"22","author":"Richetta","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1468-3083.2010.03671.x","article-title":"On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges","volume":"24","author":"Pathirana","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","article-title":"National Psoriasis Foundation Medical Board. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Rosenbach","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the 3-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"6","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2012.10940.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2012.10940.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2012.10940.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:55:28Z","timestamp":1676382928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/167\/2\/417\/6614051"}},"subtitle":["Biologics in erythrodermic psoriasis"],"short-title":[],"issued":{"date-parts":[[2012,6,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10940.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,11]]}}}